Today at Tech World @ CES 2026 at Sphere in Las Vegas, Lenovo unveiled the boldest innovations yet for the future of Hybrid AI, introducing a new personal AI super agent, AI PCs and smartphones, proofs of concept including agentic-native wearables, next-generation enterprise AI infrastructure, and breakthrough industry collaborations in entertainment and sports. Building on years of AI innovation across devices, infrastructure, solutions, and services, Lenovo demonstrated how AI is now person...

Lenovo today announced the next phase of its Hybrid AI Advantage™ with the launch of Lenovo Agentic AI, a new full-lifecycle enterprise solution for creating, deploying, and managing AI agents, and Lenovo xIQ a new suite of AI-native delivery platforms designed to simplify, accelerate, and operationalize AI across the enterprise. This evolution extends Lenovo’s established Hybrid AI Advantage™ from a foundational AI architecture to a more complete, lifecycle-driven approach for deploying and sc...

Today at Tech World @ CES 2026 at Sphere in Las Vegas, Lenovo (HKSE: 992) (ADR: LNVGY) unveiled the Lenovo AI Cloud Gigafactory with NVIDIA, expanding and reinforcing its partnership with NVIDIA through a shared commitment to accelerating hybrid AI adoption across personal, enterprise and public AI platforms. During his keynote, Lenovo Chairman and CEO Yuanqing Yang, joined by NVIDIA founder and CEO Jensen Huang, debuted this new gigawatt-scale AI factory program as a major advancement that e...

At CES® 2026, Lenovo™ unveiled a sweeping lineup of innovations across its wide portfolio, introducing smarter new personal AI experiences, first-of-its-kind proofs-of-concept, and major updates across its gaming, mobile, consumer, and commercial devices. From ThinkPad™ to ThinkBook™, ThinkCentre™, Yoga™, IdeaPad™, Legion, and Motorola, Lenovo is showing how its Smarter AI for All vision is coming to life through more adaptive devices, bold new form factors, and AI software experiences designed...

Sisvel is pleased to announce the appointment of Heath Hoglund as the company’s first-ever Chief Intellectual Property Officer. In this role he will be fully responsible for the firm’s patent pools on a global basis. One of the world’s top IP dealmakers, Hoglund joins Sisvel having taken the decision to leave Via Licensing, where he was an outstanding President for four years. Prior to that, he had been Vice-President of IP and Standards at Dolby, overseeing the company’s patent portfolio, it...

Quantum computers, with their unprecedented processing power, will ultimately challenge today’s encryption standards. This is why Thales welcomes the CES 2026 recognition awarded to the new post-quantum–ready security chip from Samsung Electronics' System LSI Business, which embeds Thales’ secure operating system and quantum-resistant cryptographic libraries. This breakthrough represents a major step forward in protecting connected devices against both current cyberattacks and tomorrow’s quantu...

Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market...

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190...

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service ag...

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting p...